Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Weller, Johannes, Bachurski, Daniel ORCID: 0000-0001-9168-9680, Shakeri, Farhad ORCID: 0000-0003-1161-1942, Schaub, Christina, Hau, Peter, Buness, Andreas, Schlegel, Uwe, Steinbach, Joachim-Peter, Seidel, Clemens, Goldbrunner, Roland, Schaefer, Niklas, Wechsler-Reya, Robert J., Hallek, Michael ORCID: 0000-0002-7425-4455, Scheffler, Bjoern, Glas, Martin, Haeberle, Lothar, Herrlinger, Ulrich, Coch, Christoph, Reiners, Katrin S. and Hartmann, Gunther (2023). A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. Int. J. Cancer, 152 (2). S. 308 - 320. HOBOKEN: WILEY. ISSN 1097-0215

Full text not available from this repository.

Abstract

Detection of tumor progression in patients with glioblastoma remains a major challenge. Extracellular vesicles (EVs) are potential biomarkers and can be detected in the blood of patients with glioblastoma. In our study, we evaluated the potential of serum-derived EVs from glioblastoma patients to serve as biomarker for tumor progression. EVs from serum of glioblastoma patients and healthy volunteers were separated by size exclusion chromatography and ultracentrifugation. EV markers were defined by using a proximity-extension assay and bead-based flow cytometry. Tumor progression was defined according to modified RANO criteria. EVs from the serum of glioblastoma patients (n = 67) showed an upregulation of CD29, CD44, CD81, CD146, C1QA and histone H3 as compared to serum EVs from healthy volunteers (P value range: <.0001 to .08). For two independent cohorts of glioblastoma patients, we noted upregulation of C1QA, CD44 and histone H3 upon tumor progression, but not in patients with stable disease. In a multivariable logistic regression analysis, a combination of CD29, CD44, CD81, C1QA and histone H3 correlated with RANO-defined tumor progression with an AUC of 0.76. Measurement of CD29, CD44, CD81, C1QA and histone H3 in serum-derived EVs of glioblastoma patients, along with standard MRI assessment, has the potential to improve detection of true tumor progression and thus could be a useful biomarker for clinical decision making.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Tzaridis, TheophilosUNSPECIFIEDorcid.org/0000-0001-9651-1144UNSPECIFIED
Weller, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bachurski, DanielUNSPECIFIEDorcid.org/0000-0001-9168-9680UNSPECIFIED
Shakeri, FarhadUNSPECIFIEDorcid.org/0000-0003-1161-1942UNSPECIFIED
Schaub, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hau, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buness, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlegel, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steinbach, Joachim-PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seidel, ClemensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldbrunner, RolandUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaefer, NiklasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wechsler-Reya, Robert J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDorcid.org/0000-0002-7425-4455UNSPECIFIED
Scheffler, BjoernUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glas, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haeberle, LotharUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herrlinger, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Coch, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiners, Katrin S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hartmann, GuntherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-691703
DOI: 10.1002/ijc.34261
Journal or Publication Title: Int. J. Cancer
Volume: 152
Number: 2
Page Range: S. 308 - 320
Date: 2023
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1097-0215
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
NEWLY-DIAGNOSED GLIOBLASTOMA; TEMOZOLOMIDE; EXOSOMES; CONCOMITANTMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69170

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item